期刊
THERAPEUTIC ADVANCES IN HEMATOLOGY
卷 13, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/20406207221112899
关键词
Acute myeloid leukemia (AML); myelodysplastic syndrome (MDS); NEDD8 activating enzyme (NAE) inhibitor; pevonedistat
类别
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder with limited treatment options. Pevonedistat, a novel inhibitor of NEDD8 activating enzyme, has shown promising potential in improving clinical outcomes by inhibiting the cell cycle and inducing apoptosis.
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder clinically defined by cytopenias, bone marrow failure, and an increased risk of progressing to acute myeloid leukemia (AML). Traditionally, first-line treatment for patients with higher-risk MDS has been hypomethylating agents (HMAs). However, these agents have modest clinical activity as single agents. A one-size-fits-all treatment paradigm is insufficient for such a heterogeneous disease in the modern era of precision medicine. Several new agents have been developed for MDS with the hopes of improving clinical outcomes and survival. Pevonedistat is a first-in-class, novel inhibitor of neuronal precursor cell-expressed developmentally down-regulated protein-8 (NEDD8) activating enzyme (NAE) blocking the neddylation pathway leading to downstream effects on the ubiquitin-proteosome pathway. Pevonedistat ultimately leads to apoptosis and inhibition of the cell cycle in cancer cells. Studies have demonstrated the safety profile of pevonedistat, leading to the development of multiple trials investigating combination strategies with pevonedistat in MDS and AML. In this review, we summarize the preclinical and clinical rationale for pevonedistat in MDS and AML, review the clinical data of this agent alone and in combination with HMAs to date, and highlight potential future directions for this agent in myeloid malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据